GRACEcast
Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit cancerGRACE.org for more info.

Dr. David Spigel, Sarah Cannon Cancer Center, describes which molecular markers he seeks for NSCLC patients.


Dr. Jared Weiss from the University of North Carolina, Chapel Hill reviews results from HPV-positive patients with head and neck cancer (HNSCC) from recent trials and describes emerging research in this population.

Direct download: GRACEcast-158_HeadNeck-Video_HPV_HNSCC_Clinical_Trials.m4v
Category:Head-Neck-Video -- posted at: 1:41pm PST

Dr. Jared Weiss from the University of North Carolina, Chapel Hill reviews results from HPV-positive patients with head and neck cancer (HNSCC) from recent trials and describes emerging research in this population.

Direct download: GRACEcast-158_HeadNeck-Audio_HPV_HNSCC_Clinical_Trials.mp3
Category:Head-Neck-Audio -- posted at: 1:41pm PST

Dr. Jared Weiss from the University of North Carolina, Chapel Hill introduces us to the human papilloma virus and its role as a cause and relevant prognostic factor for head and neck cancer (HNSCC).

Direct download: GRACEcast-157_HeadNeck-Video_HPV_Introduction_HNSCC_Weiss.m4v
Category:Head-Neck-Video -- posted at: 1:40pm PST

GRACE, cancerGRACE, GRACEcast, Jared Weiss, Unveristy of North Carolina-Chapel Hill, UNC-Chapel Hill, induction therapy, neoadjuvant therapy, head and neck cancer, HNSCC, carbplatin, paclitaxel, cetuximab, Taxol, Erbitux, weekly

Direct download: GRACEcast-157_HeadNeck-Audio_HPV_Introduction_HNSCC_Weiss.mp3
Category:Head-Neck-Audio -- posted at: 1:40pm PST

Dr. Jared Weiss from the University of North Carolina, reviews several options as induction therapy for head and neck cancer and focuses on the potential appeal and tolerability of the combination of weekly carboplatin and paclitaxel with cetuximab.

Direct download: GRACEcast-156_HeadNeck-Video_Induction_Chemo_HNSCC_Weiss_2.m4v
Category:Head-Neck-Video -- posted at: 10:42am PST

Dr. Jared Weiss from the University of North Carolina, reviews several options as induction therapy for head and neck cancer and focuses on the potential appeal and tolerability of the combination of weekly carboplatin and paclitaxel with cetuximab.

Direct download: GRACEcast-156_HeadNeck-Audio_Induction_Chemo_HNSCC_Weiss_2.mp3
Category:Head-Neck-Audio -- posted at: 10:42am PST

Dr. Jared Weiss from the University of North Carolina, Chapel Hill reviews the rationale for induction chemotherapy before surgery for head and neck cancer and highlights the early work that led to the emergence of the TPF regimen in this setting.

Direct download: GRACEcast-155_HeadNeck-Video_Induction_Chemo_HNSCC_Weiss_1.m4v
Category:Head-Neck-Video -- posted at: 2:06pm PST

Dr. Jared Weiss from the University of North Carolina, Chapel Hill reviews the rationale for induction chemotherapy before surgery for head and neck cancer and highlights the early work that led to the emergence of the TPF regimen in this setting.

Direct download: GRACEcast-155_HeadNeck-Audio_Induction_Chemo_HNSCC_Weiss_1.mp3
Category:Head-Neck-Audio -- posted at: 2:05pm PST

Dr. Ravi Salgia, from the University of Chicago, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.


Dr. Sarah Goldberg gives her view on more widespread availability of new mutation tests, provides her perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for other LC subtypes.


Dr. Bob Doebele from the University of Colorado, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.


Drs. Ross Camidge and Corey Langer describe which patients with advanced NSCLC they seek molecular marker testing on.


Dr. Greg Riely, from Memorial Sloan-Kettering, gives her view on more widespread availability of new mutation tests.


Drs. Mary Pinder, Nate Pennell, and Jack West discuss whether the finding of improving progression-free survival with maintenance sorafenib for SCLC should change the standard of care for treatment of extensive stage disease.


Drs. Jack West, Mary Pinder, and Nate Pennell review various ways in which emerging immunotherapies could be effectively incorporated into our treatment strategies for lung cancer, potentially adding to or replacing current options.


Drs. Jack West, Mary Pinder, and Nate Pennell discuss options for managing acquired resistance to EGFR TKIs and ALK inhibitors in patients with advanced NSCLC and a driver mutation.


Drs. Nate Pennell, Mary Pinder, and Jack West discuss the START trial of L-BLP-25 (tecemotide) immunotherapy in locally advanced NSCLC.

Direct download: GRACEcastUC-146_Lung-Video_START_Trial_ASCO_2013.m4v
Category:Lung-Cancer-Video -- posted at: 11:35am PST

Dr. Phil Bonomi, from Rush University, reviews his thought process in recommending a repeat biopsy after progression for patients with advanced lung cancer.


Dr. Rosalyn Juergens, McMaster University, reviews how she discusses the potential advantages and disadvantages waiting on molecular marker results and sometimes seeking additional tissue in patients with advanced NSCLC.


Drs. Mary Pinder, Nate Pennell, and Jack West discuss developments with selumetinib and other MEK inhibitors as a potential target for the 20-25% of NSCLC patients with a KRAS mutation.

Direct download: GRACEcastUC-144_Lung-Video_MEK_Inhibitor_Update_ASCO_2013.m4v
Category:Lung-Cancer-Video -- posted at: 11:43pm PST

Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.